What's in HuniLife Biotechnology, Inc.'s pipeline?

HuniLife Biotechnology, Inc. has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with HuniLife Biotechnology, Inc.'s portfolio?

Top competitors by shared drug class: King Faisal Specialist Hospital & Research Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hunilife-biotechnology-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

HuniLife Biotechnology, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HuniLife Biotechnology, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Lenalidomide and Dexamethasone	Lenalidomide and Dexamethasone	phase 3	Immunomodulatory agent + corticosteroid combination	Cereblon (CRBN), TNF-α pathway; glucocorticoid receptor	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

King Faisal Specialist Hospital & Research Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for HuniLife Biotechnology, Inc.:

Cite this brief

Drug Landscape (2026). HuniLife Biotechnology, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hunilife-biotechnology-inc. Accessed 2026-05-17.